GlassScriptPhysician profile
Amelia Bostwick
NPI 1346485679
$12,022.71
in general payments reported to CMS, 2019-2025
29 companies · $1,131 in 2025
The $1,131 reported for 2025 was more than what 91% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $120 · 2021: $7,591 · 2022: $714 · 2023: $1,158 · 2024: $1,198 · 2025: $1,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,442 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,441.86 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,212.57 | 2021 | |
| Sumitomo Pharma America, INC. | $2,277.99 | 2023-2025 | Myfembree, Gemtesa |
| Myovant Sciences INC. | $650.85 | 2021-2022 | |
| Sage Therapeutics, LLC | $244.46 | 2024-2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $192.41 | 2022-2025 | Acessa Provu System, Thinprep 2000 Processor, Myosure Tissue Removal Device |
| Abbvie INC. | $181.04 | 2020-2024 | Lo Loestrin Fe, Orilissa |
| Shield Therapeutics INC | $152.67 | 2022-2024 | Accrufer |
| Astellas Pharma US INC | $152.20 | 2022-2025 | Veozah |
| Lilly USA, LLC | $112.04 | 2020-2025 | Zepbound, Trulicity, Mounjaro |
| Avanos Medical | $110.62 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $98.43 | 2020-2023 | |
| Novo Nordisk INC | $93.92 | 2021-2025 | Wegovy |
| Agile Therapeutics, INC. | $83.50 | 2021-2023 | Twirla |
| Evofem Biosciences, INC. | $64.10 | 2021 | |
| Organon LLC | $52.53 | 2025 | Nexplanon |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $47.48 | 2023 | Dermabond Prineo, Vistaseal |
| Millicent US INC | $40.61 | 2024-2025 | Femlyv, Intrarosa, Femring |
| Pfizer INC. | $39.24 | 2021-2025 | |
| Exeltis, USA INC. | $34.74 | 2021 | |
| Smith+Nephew, INC. | $26.96 | 2023 | Stravix |
| Vertex Pharmaceuticals Incorporated | $21.86 | 2024 | |
| Boston Scientific Corporation | $20.65 | 2024 | |
| Amag Pharmaceuticals, INC. | $18.62 | 2020 | |
| Lupin INC. | $17.66 | 2021 | |
| Lsi Solutions INC | $16.48 | 2025 | Fornisee |
| Scynexis, INC. | $16.39 | 2022 | |
| Dermira, INC. | $15.38 | 2020 | |
| Amgen INC. | $14.37 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amelia Bostwick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.